Toronto Dominion Bank Grows Holdings in Hologic, Inc. (HOLX)

Toronto Dominion Bank raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 119,035 shares of the medical equipment provider’s stock after purchasing an additional 12,666 shares during the period. Toronto Dominion Bank’s holdings in Hologic were worth $5,088,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Parnassus Investments CA raised its position in shares of Hologic by 88.6% in the 4th quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock valued at $608,797,000 after acquiring an additional 6,689,454 shares during the period. Victory Capital Management Inc. raised its position in shares of Hologic by 5.8% in the 4th quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock valued at $265,008,000 after acquiring an additional 342,239 shares during the period. Pictet Asset Management Ltd. raised its position in shares of Hologic by 50.3% in the 3rd quarter. Pictet Asset Management Ltd. now owns 2,912,338 shares of the medical equipment provider’s stock valued at $106,854,000 after acquiring an additional 974,325 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Hologic by 5.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,969,026 shares of the medical equipment provider’s stock valued at $72,243,000 after acquiring an additional 105,360 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Hologic by 3.5% in the 3rd quarter. Legal & General Group Plc now owns 1,426,469 shares of the medical equipment provider’s stock valued at $52,333,000 after acquiring an additional 48,577 shares during the period. Institutional investors own 95.24% of the company’s stock.

A number of analysts recently weighed in on the stock. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 price target on the stock in a research report on Wednesday, December 20th. Deutsche Bank downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research report on Friday, January 19th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Stifel Nicolaus downgraded shares of Hologic from a “buy” rating to a “hold” rating and cut their price target for the company from $45.00 to $42.00 in a research report on Friday, February 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price target on shares of Hologic in a research report on Friday, November 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $48.00.

In related news, Director Namal Nawana bought 6,600 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were purchased at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the acquisition, the director now owns 6,954 shares of the company’s stock, valued at approximately $263,417.52. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.88% of the company’s stock.

Shares of Hologic, Inc. (NASDAQ:HOLX) opened at $38.87 on Wednesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25. The company has a market cap of $10,864.83, a P/E ratio of 10.26, a price-to-earnings-growth ratio of 1.77 and a beta of 0.77. Hologic, Inc. has a fifty-two week low of $35.33 and a fifty-two week high of $46.80.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, topping the consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million for the quarter, compared to the consensus estimate of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the company posted $0.52 EPS. equities analysts anticipate that Hologic, Inc. will post 2.25 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Toronto Dominion Bank Grows Holdings in Hologic, Inc. (HOLX)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/21/toronto-dominion-bank-grows-holdings-in-hologic-inc-holx.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply